News

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

The leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, announced the construction of Vectura, a new state of the art 4,000m2 facility.

The new facility is built to enable Polyplus-transfection® to continue to cater for the exponential growth in demand for raw materials for ATMP development and manufacturing. Following completion of the facility, Polyplus will be able to meet the expectations of the gene and cell therapy market moving from late-stage clinical development into commercialization as well as ongoing increases in R&D and preclinical gene therapy development. The facility will also house Polyplus-transfection®’s head office, managing its international operations and delivery of transfection reagents to cell and gene therapy organizations around the globe.
The new facility will fulfill several immediate priorities for Polyplus. These priorities include doubling its headcount both in its gene and cell therapy transfection reagent manufacturing and development departments. It will also provide significant additional manufacturing capacity for ex vivo and in vivo therapy products. This will increase Polyplus’ production capacity to manufacture and deliver transfection solutions to target a wide range of diseases globally. In the new facility, R&D and laboratory space will increase by over 300%.

News

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

Learn more

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

A prolific period for researchers, confinement has allowed the Etablissement Français du Sang teams to generate and mature many ideas from pre-existing research. In Besançon, Marina Deschamps and Christophe Ferrand...

Learn more